Ab&B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine – First Dual-Approved Candidate Globally
Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced that China’s National Medical Products Administration (NMPA) has...
China Medical System’s Silvemimab Becomes World’s First Dual-Epitope Fully Human Rabies Antibody Approved in China
China Medical System Holdings Limited (HKG: 0867) announced that the National Medical Products Administration (NMPA)...
Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital
Fusen Pharmaceutical Group Limited (HKG: 1652) announced a RMB 300 million capital increase agreement for...
Biokin Secures World’s First EGFR×HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its first-in-class (FIC) Class 1 therapeutic...
China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted
The National Organized Drug Joint Procurement Office announced the 12th batch of national organized drug...
Pierre Fabre Secures European Commission Approval for Braftovi Combination in BRAF-Mutant Colorectal Cancer
Pierre Fabre announced that the European Commission (EC) has approved Braftovi (encorafenib) in combination with...
Hengrui’s Rezvilutamide Receives EMA Acceptance for Metastatic Prostate Cancer Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the European Medicines Agency...
AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline
AbbVie Inc. (NYSE: ABBV) and Apogee Therapeutics, Inc. (NASDAQ: APGE) announced a definitive agreement for...
BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform
BioArctic AB (OTCMKTS: BRCTF) announced a strategic research and collaboration agreement with Eli Lilly and...
CARsgen Therapeutics Secures World’s First Solid Tumor CAR-T Approval with Kylimei for Gastric Cancer
CARsgen Therapeutics Holdings Limited (HKG: 2171) announced that its CAR-T therapy Kylimei (satricabtagene autoleucel injection)...
Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced an exclusive global licensing agreement with U.S.-based...
MacroGenics Secures $24.5M Milestone from Sanofi Following FDA Approval Expansion for Tzield in Type 1 Diabetes
MacroGenics, Inc. (NASDAQ: MGNX) announced it will receive a USD 24.5 million regulatory milestone payment...
Pfizer Reports Mixed Phase 3 Results for Sigvotatug Vedotin in Non-Small Cell Lung Cancer
Pfizer Inc. (NYSE: PFE) announced topline results from the Phase 3 SigVie-002 study (formerly Be6A...
Anhui Province Launches National Alliance for Monoclonal Antibody Biologics Volume-Based Procurement
The Anhui Provincial Healthcare Security Administration has formally invited other provinces to participate in a...
Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6×CD3 Bispecific T-Cell Engager
Antengene Corporation (HKG: 6996) announced a strategic global licensing agreement with US-based K2 Therapeutics for...
CSPC Innovation Pharmaceutical Files Hong Kong IPO Prospectus Following Strategic Evolution from Caffeine Producer to Biopharmaceutical Player
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group (HKG: 1093), has released...
Zhiyi Biotechnology Files Hong Kong IPO Prospectus as China’s Leading Live Biotherapeutic Products Developer
Guangzhou Zhiyi Biotechnology Co., Ltd. announced the release of its initial public offering (IPO) prospectus...
Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio
Gan & Lee Pharmaceuticals (SHA: 603087) announced that the Ministry of Health and Prevention (MOHAP)...
Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced the presentation of compelling clinical data for...
Innovent Biologics Doses First Patient in Pivotal Phase III Trial for IBI3003 Trispecific Antibody in Relapsed/Refractory Multiple Myeloma
Innovent Biologics (HKG: 1801) announced the first subject dosing in the pivotal Phase III TriadicMM-1...